Company intelligence / Profile preview

Tibet Haisco

Shannan, Tibet Autonomous Region, China

Ownership: Private
Development stage: Other

Overview

Tibet Haisco is engaged in drug development primarily in oncology, respiratory, immunology, endocrinology, and nervous system diseases. Lead assets have reached Phase 2; lead program HSK39775 (USP1 inhibitor) is in Phase 2 for advanced malignant solid neoplasm. There are additional programs in Phase 2 for chronic obstructive pulmonary disease and several assets in earlier stages.[4]

Therapeutic areas: ImmunologyEndocrinologyHematologyPulmonologyOncologyNeurology
Modalities: Small moleculeRecombinant polypeptideChemical drug
Industry: Biotech

Beyond the preview

Go deeper on Tibet Haisco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tibet Haisco.

Explore the full profile